diabetes

Eyles, E., Margelyte, R., Edwards, H. B., Moran, P. A., Kessler, D. S., Davies, S. J. C., et al. (2023). Antipsychotic Medication and Risk of Metabolic Disorders in People With Schizophrenia: A Longitudinal Study Using the UK Clinical Practice Research Datalink. Schizophr Bull. http://doi.org/10.1093/schbul/sbad126

View

Chudasama, Y. V., Khunti, K., Coles, B., Gillies, C. L., Islam, N., Rowlands, A. V., et al. (2023). Life expectancy following a cardiovascular event in individuals with and without type 2 diabetes: A UK multi-ethnic population-based observational study. Nutr Metab Cardiovasc Dis. http://doi.org/10.1016/j.numecd.2023.04.003

View

Cao, T. X. D., Filliter, C., Montastruc, F., H. Y. Yu, O., Fergusson, E., Rej, S., et al. (2022). Selective serotonin reuptake inhibitors and the risk of type 2 diabetes mellitus in youths. J Affect Disord, 318, 231-237. http://doi.org/10.1016/j.jad.2022.08.094

View

James, G., Kim, J., Mellström, C., Ford, K. L., Jenkins, N. C., Tsang, C., et al. (2022). Serum potassium variability as a predictor of clinical outcomes in patients with cardiorenal disease or diabetes: a retrospective UK database study. Clin Kidney J, 15, 758-770. http://doi.org/10.1093/ckj/sfab225

View